Diagonal Therapeutics Inc.’s DIAG-723 has been awarded orphan drug designation by the FDA for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the EMA has provided a ...

WATERTOWN, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying ...

‍ About Hereditary Hemorrhagic Telangiectasia (HHT) HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies.

WATERTOWN, Mass. , March 04, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with multispecific antibodies that address the ...

There's so much delightful intrigue to uncover with Cabernet 's core message of monsters being hereditary, a concept that initially seems solely meant to draw parallels between the protagonist's ...

ANDEMBRY ® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation ...

WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies to address the root cause ...

BASEL, Switzerland, Nov. 18, 2024 /PRNewswire/ -- Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focusing on treatments for rare diseases associated with vascular ...

News provided by Vaderis Therapeutics AG 18 Nov, 2024, 13:00 GMT ...

Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focusing on treatments for rare diseases associated with vascular malformations, today announces that the US Food and Drug ...

Conversely, in prehospital settings, video laryngoscopy had a lower first-attempt success rate than direct laryngoscopy (RR, 0.75; 95% CI, 0.57-0.99).